Peripherally Acting Opioid Compounds Avoiding Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid compounds often have central side effects due to their action on the brain, limiting their therapeutic potential for treating peripheral pain and opioid-related disorders without causing undesirable central nervous system effects.
Innovation Solution
Development of peripherally acting opioid compounds that modulate opioid receptors without crossing the blood-brain barrier, specifically compounds of Formula I, which are designed to bind to opioid receptors in the periphery, providing analgesia and treating conditions like pain, addiction, and gastrointestinal disorders without central side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical opioids are administered to achieve potent antinociceptive effects, then pain relief is improved, but central side effects worsen
Solution Approach 1:
The patent segments the opioid system into central and peripheral components by designing compounds that selectively target peripheral opioid receptors (OPRs) on sensory neurons while avoiding penetration of the blood-brain barrier. This spatial segmentation allows antinociceptive effects at the site of pain without central nervous system involvement, resolving the contradiction between effective pain relief and avoidance of central side effects
Solution Approach 2:
The invention applies local quality by creating opioids with specific physicochemical properties (high polarity, specific molecular structure as shown in Formula I) that enable selective action at peripheral sites. The compounds are designed to interact with OPRs located on peripheral nerve terminals and in gastrointestinal tissues while maintaining exclusion from central sites, thus providing localized therapeutic action without systemic central effects
2Reliability
If opioids cross the blood-brain barrier to access central receptors, then central analgesia is improved, but central side effects worsen
Solution Approach 1:
The patent extracts the peripheral analgesic function from the central opioid system by designing compounds that exclusively target peripheral opioid receptors. The molecular structure in Formula I is specifically engineered to bind OPRs with high affinity while being physically excluded from crossing the blood-brain barrier, thereby separating the therapeutic antinociceptive effect from the harmful central side effects that accompany traditional central-acting opioids
3Object-affected harmful factors
If peripherally acting opioid compounds are designed to avoid the blood-brain barrier, then central side effects are reduced, but penetration to central receptors is prevented
Solution Approach 1:
The invention inverts the traditional approach by designing opioids that deliberately cannot access central receptors. Instead of trying to enhance blood-brain barrier penetration for central analgesia, the compounds are engineered with properties that ensure peripheral selectivity, achieving therapeutic effect through the opposite route - peripheral rather than central action - thus resolving the contradiction by making central penetration unnecessary
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat peripheral pain and opioid-related disorders with reduced risk of central side effects, offering potent analgesia and modulation of opioid receptor activity while avoiding brain interaction.
Implementation Method 1
compounds of Formula I, which are designed to bind to opioid receptors in the periphery, providing analgesia and treating conditions like pain, addiction, and gastrointestinal disorders without central side effects
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a compound of Formula (I), (II), (III), (IV) or a pharmaceutically acceptable ester or prodrug thereof.